Summary:
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD.
Qualified Participants Must:
• Be diagnosed with Alzheimer's disease
•
Be between 50 and 85 years of age (Adult, Senior)
Qualified Participants May Receive:
Study-related medical care and investigational drug at no cost and may be compensated for time and travel.